[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Views 1,067
Citations 0
Correction
July 24/31, 2018

Incomplete Reporting of Potential Conflicts of Interest

JAMA. 2018;320(4):409. doi:10.1001/jama.2018.9757

In the Viewpoint entitled “Pharmaceutical Marketing for Rare Diseases: Regulating Drug Company Promotion in an Era of Unprecedented Advertisement,”1 the conflict of interest disclosures paragraph was incomplete. The paragraph should read as follows: “Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Mailankody was supported in part by the National Cancer Institute MSK Cancer Center Support Grant/Core Grant (P30 CA008748). Dr Prasad reports receiving royalties from his book Ending Medical Reversal; that his work is funded by the Laura and John Arnold Foundation; that he has received honoraria for grand rounds/lectures from several universities, medical centers, and professional societies; and that he is not compensated for his work at the Veterans Affairs Medical Center in Portland, Oregon, or the Health Technology Assessment Subcommittee of the Oregon Health Authority.” A letter of explanation appears in this issue of JAMA.2 This article was corrected online.

References
1.
Mailankody  S, Prasad  V.  Pharmaceutical marketing for rare diseases: regulating drug company promotion in an era of unprecedented advertisement.  JAMA. 2017;317(24):2479-2480. doi:10.1001/jama.2017.5784PubMedGoogle ScholarCrossref
2.
Prasad  V.  Inconsistent reporting of potential conflicts of interest  [published July 24, 2018].  JAMA. doi:10.1001/jama.2018.9526Google Scholar
×